Abcam’s Tissue type Plasminogen Activator Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for accurate quantitative measurement of Human Tissue type Plasminogen Activator concentrations in Cell culture supernatant and serum.
Tissue type Plasminogen Activator specific antibody has been precoated onto 96-well plates. Standards and test samples are added to the wells along with an HRP-conjugated Tissue type Plasminogen Activator detection antibody and the microplate is then incubated at room temperature and unbound proteins are then washed away with a wash buffer. TMB is then added and catalyzed by HRP to produce a blue color product that subsequently changes to yellow after addition of acidic stop solution. The density of yellow coloration is directly proportional to the Tissue type Plasminogen Activator amount of sample captured on the plate.
Get higher sensitivity in only 90 minutes with Human Tissue Plasminogen Activator ELISA Kit (ab190812) from our SimpleStep ELISA® range.
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.
Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
Involvement in disease
Note=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
Both FN1 and one of the kringle domains are required for binding to fibrin. Both FN1 and EGF-like domains are important for binding to LRP1. The FN1 domain mediates binding to annexin A2. The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.
The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa. Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin. N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor. Characterization of O-linked glycan was studied in Bowes melanoma cell line.